Search
Harrow Inc
HROWAdd to Watchlist
42.870USD
+0.930+2.22%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.60BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Harrow Inc is 8.75, ranking 9 out of 157 in the Pharmaceuticals industry. The average price target is 69.00, with a high of 94.00 and a low of 59.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
65.571
Target Price
+56.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Harrow Inc
HROW
8
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Harrow Inc's expected revenue for the next quarter?
Harrow Inc's expected revenue is 70.95M.
What is Harrow Inc's price target?
Analysts forecast that Harrow Inc's price target is USD 69.00, with the highest forecast at USD 94.00 and the lowest forecast at USD 59.00.
How have Harrow IncHROW's recent earnings per share performed?
The market expectation was USD -0.74, while Harrow IncHROW's earnings per share (EPS) for the previous quarter was USD 0.18. EPS for the next quarter is expected at USD -0.17.
What is the analyst rating for Harrow Inc?
Based on the ratings of Harrow Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
